Sofinnova leads £6m investment in Mission Therapeutics
Sofinnova Partners has led a £6m funding round for Cambridge-based drug development company Mission Therapeutics.
Also participating in the round are Imperial Innovations, which provided £1.3m, SR One and Roche Venture Fund. Imperial Innovations owns a 15.7% stake in the company going forward.
The funding will support the company as it looks to further progress in its drug development operations.
Company
Mission Therapeutics is a spin-out from the University of Cambridge and is developing a platform of technologies for the discovery and development of modulators of enzymes involved in cancer and other diseases.
Founded in 2011, the company is based at the Babraham Research Campus, seven miles south of Cambridge.
People
Susan Searle is CEO of Imperial Innovations.
More on UK / Ireland
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater